Retatrutide Cost in South Dakota (2026): Pricing, Insurance, and Savings Guide

What Does Retatrutide Cost in South Dakota Right Now?

Retatrutide does not yet have a confirmed retail price in South Dakota because the drug has not received full FDA approval for commercial sale. Eli Lilly has not published a manufacturer list price. South Dakota residents can estimate future costs by examining the pricing of other GLP-1 receptor agonists already on the market.

Semaglutide (Wegovy) carries a list price of approximately $1,349 per month, while tirzepatide (Zepbound), also manufactured by Eli Lilly, launched at a list price of $1,059.87 for maintenance doses 1. Analysts expect retatrutide to land within a similar bracket, though Lilly's pricing strategy for Zepbound suggests the company may position retatrutide competitively to capture market share. The once-weekly injection format matches tirzepatide's dosing schedule, which means fulfillment infrastructure for South Dakota pharmacies should mirror what already exists for Zepbound.

Compounded versions of retatrutide represent the only current path to access in South Dakota. Licensed 503A compounding pharmacies operating within the state can legally prepare patient-specific prescriptions when a prescriber determines medical necessity. Compounded pricing typically ranges from $200 to $500 per month depending on dose, though exact figures vary by pharmacy. South Dakota's Board of Pharmacy regulates these facilities under existing state compounding statutes 2.

Cash-pay patients at retail pharmacies will need to wait for commercial availability. No South Dakota retail pharmacy currently stocks branded retatrutide.

Phase 2 Clinical Data: Why the Price Expectations Are High

The Jastreboff et al. phase 2 trial published in the New England Journal of Medicine in June 2023 established retatrutide as the most potent weight-loss injectable studied to date. Participants receiving the highest dose (12 mg) lost a mean of 24.2% of body weight at 48 weeks, compared to 2.1% in the placebo arm (N=338) 2. That result exceeded the 22.5% loss seen with tirzepatide 15 mg in the SURMOUNT-1 trial at 72 weeks 3.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center and lead investigator, stated: "The magnitude of weight reduction observed with retatrutide at 48 weeks is unprecedented among anti-obesity medications studied in randomized trials" 2.

Retatrutide's triple mechanism activates GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component drives additional energy expenditure and hepatic lipid oxidation beyond what dual agonists achieve. In the same phase 2 trial, participants with a baseline BMI of 30 or higher experienced mean reductions of 17.5% at the 8 mg dose and 24.2% at the 12 mg dose 2. These efficacy numbers are the primary reason analysts project premium pricing once the drug reaches market.

The phase 3 TRIUMPH program includes trials for obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes (TRIUMPH-DM), and MASLD/MASH (TRIUMPH-MASH). Results from TRIUMPH-1 and TRIUMPH-3 are expected to form the basis of the FDA submission 4.

South Dakota Medicaid Coverage for Retatrutide

South Dakota Medicaid does not cover retatrutide for chronic weight management. This applies to both fee-for-service Medicaid and managed care plans operating in the state. The exclusion is consistent with South Dakota Medicaid's broader stance on anti-obesity medications, which historically have not appeared on the state's preferred drug list 5.

The Treat and Reduce Obesity Act, reintroduced in Congress multiple times, would require Medicare Part D to cover FDA-approved anti-obesity medications. If passed, this federal change could pressure state Medicaid programs to follow. South Dakota has not independently signaled any intention to add obesity pharmacotherapy to its formulary.

For Medicaid beneficiaries in South Dakota, the practical options are limited. Retatrutide prescribed off-label for type 2 diabetes management (if approved for that indication) might receive different formulary consideration, since South Dakota Medicaid does cover GLP-1 agonists for glycemic control. The distinction between obesity and diabetes indications will matter when the drug launches.

Dr. Robert Kushner, professor of medicine at Northwestern University, has noted: "State Medicaid coverage of anti-obesity medications remains the single largest barrier to equitable access, affecting millions of patients who would otherwise qualify for treatment" 6.

South Dakota residents enrolled in Medicaid should contact the state's Department of Social Services to request a prior authorization review once FDA approval occurs, as formulary decisions can shift rapidly after new drug launches.

Is Compounded Retatrutide Legal in South Dakota?

Compounded retatrutide is legal in South Dakota when dispensed by a licensed 503A pharmacy operating under a valid patient-specific prescription. Federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare customized medications for individual patients when certain conditions are met 7.

South Dakota's Board of Pharmacy oversees 503A facilities within state borders. These pharmacies must compound from bulk drug substances that meet USP standards, maintain proper licensing, and dispense only upon receipt of a valid prescription from a licensed prescriber. The pharmacy cannot advertise or promote compounded retatrutide, and the preparation must be for an individually identified patient.

A few caveats apply. The FDA has taken enforcement action against compounders producing GLP-1 medications using substandard ingredients or operating without proper licensure. In 2024, the agency issued warning letters to multiple compounding pharmacies nationwide for violations related to semaglutide and tirzepatide production 7. South Dakota patients should verify that any 503A pharmacy they use holds current state licensure and sources pharmaceutical-grade ingredients.

503B outsourcing facilities, which can compound without patient-specific prescriptions, represent a separate regulatory category. These facilities face stricter FDA oversight, including current good manufacturing practice (cGMP) requirements. Several 503B operations supply compounded peptides to clinics across South Dakota via interstate commerce.

Pricing for compounded retatrutide through 503A pharmacies in South Dakota generally falls between $200 and $500 per month. The exact cost depends on the prescribed dose, injection concentration, and the pharmacy's compounding fees. Patients should request a certificate of analysis for each batch to confirm peptide purity and potency.

Telehealth Access to Retatrutide in South Dakota

South Dakota permits telehealth prescribing of retatrutide. The state's telehealth parity laws, expanded during the COVID-19 public health emergency and made permanent through subsequent legislation, allow licensed prescribers to evaluate patients and write prescriptions via audio-video consultations 8.

For South Dakota residents, this means a physician, nurse practitioner, or physician assistant licensed in the state can prescribe retatrutide after a telehealth visit. The prescriber must hold an active South Dakota medical license or practice under an interstate compact agreement. The Ryan Haight Act requires at least one in-person evaluation before prescribing certain controlled substances, but anti-obesity medications like retatrutide are not scheduled, so this restriction does not apply.

Telehealth platforms operating in South Dakota typically charge $99 to $299 for an initial weight-management consultation and $49 to $149 for follow-up visits. Some platforms bundle the consultation fee with the compounded medication cost. Patients should confirm that their telehealth provider uses a pharmacy licensed in South Dakota or a state whose pharmacy board has reciprocity with South Dakota.

The practical workflow for a South Dakota patient seeking retatrutide via telehealth involves three steps: completing an intake form with medical history, BMI, and metabolic labs; attending a synchronous video consultation with a licensed prescriber; and receiving a prescription sent to either a retail pharmacy (for branded product, once available) or a compounding pharmacy. Most telehealth platforms ship directly to South Dakota addresses.

Which Insurance Plans Cover Retatrutide in South Dakota?

No commercial insurance plan in South Dakota currently lists retatrutide on its formulary because the drug lacks FDA approval. Once approved, coverage will depend on each insurer's pharmacy and therapeutics committee decisions 9.

South Dakota's insurance market includes major carriers like Avera Health Plans, Sanford Health Plan, DakotaCare, and national carriers (UnitedHealthcare, Blue Cross Blue Shield of South Dakota, Cigna, and Aetna). Coverage precedent from tirzepatide (Zepbound) offers some guidance. Sanford Health Plan and Avera Health Plans added tirzepatide for type 2 diabetes within six months of launch but initially excluded the obesity indication. Similar patterns are expected for retatrutide.

Employer-sponsored plans represent the most promising route. Large employers who self-insure can add anti-obesity medications to their formulary without waiting for carrier-level decisions. South Dakota's largest private employers, including Sanford Health, Avera Health, and several federal installations, have the scale to negotiate manufacturer rebates that make coverage financially viable.

Patients anticipating retatrutide coverage should review their plan's Summary of Benefits and Coverage document, specifically the exclusions section. Many plans contain blanket "weight-loss medication" exclusions that would need to be removed before retatrutide could be covered regardless of formulary status 10.

Prior authorization is virtually certain for any plan that does cover retatrutide. Typical criteria for GLP-1 class drugs in South Dakota include a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity), documented failure of lifestyle intervention for 3 to 6 months, and no contraindicated conditions such as personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The Eli Lilly Savings Card and South Dakota Discount Programs

Eli Lilly has operated manufacturer savings programs for tirzepatide (Zepbound and Mounjaro) that offer significant out-of-pocket reductions. The Zepbound savings card reduced monthly costs to $25 for commercially insured patients, while a separate cash-pay program launched at $399 per month for certain vial presentations 1.

A similar savings card program for retatrutide is widely expected upon commercial launch. Based on Lilly's precedent with Zepbound, South Dakota patients with commercial insurance could see co-pays between $25 and $150 per month if they meet eligibility criteria. Patients with government insurance (Medicaid, Medicare, Tricare, VA) are typically excluded from manufacturer savings cards under federal anti-kickback statutes.

South Dakota does not operate a state-level prescription assistance program specifically for obesity medications. The state's pharmaceutical assistance program focuses on Medicare beneficiaries and does not extend to anti-obesity pharmacotherapy. National programs such as Lilly Cares (Eli Lilly's patient assistance foundation) may provide free medication to qualifying low-income patients once retatrutide launches.

Pharmacy benefit managers (PBMs) active in South Dakota, including Express Scripts, CVS Caremark, and OptumRx, will negotiate rebates with Eli Lilly that influence net pricing. These rebated prices are not visible to consumers but affect formulary placement decisions. The three PBMs together process over 80% of South Dakota's prescription volume 10.

South Dakota patients can also explore clinical trial enrollment. The TRIUMPH program has study sites across the Midwest, and ClinicalTrials.gov lists active enrollment locations. Trial participants receive the medication at no cost and contribute to the evidence base that will determine FDA approval timing.

How Retatrutide Compares to Other Options Available in South Dakota

South Dakota residents currently have access to several FDA-approved weight-management medications. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo 11. Tirzepatide 15 mg (Zepbound) achieved 22.5% at 72 weeks in SURMOUNT-1 (N=2,539) 3. Retatrutide's phase 2 result of 24.2% at 48 weeks suggests it may deliver the largest effect in the shortest timeframe, though phase 3 confirmation is still pending.

The cost comparison also matters for South Dakota patients paying out of pocket. Wegovy lists at approximately $1,349 per month. Zepbound lists at $1,059.87 per month for the 10 mg and 15 mg maintenance doses. Compounded semaglutide in South Dakota runs $150 to $400 per month, while compounded tirzepatide costs $200 to $500 per month. Compounded retatrutide pricing currently overlaps with the tirzepatide range.

One differentiator: retatrutide's glucagon receptor activity may provide metabolic benefits beyond weight reduction alone. The phase 2 trial showed a mean reduction in liver fat of 42.9% at the 8 mg dose in participants with baseline hepatic steatosis, a finding particularly relevant for the estimated 25% of South Dakota adults with non-alcoholic fatty liver disease 2. This hepatic benefit could influence payer decisions to cover retatrutide for MASLD independently of the obesity indication.

Side effects were consistent with the GLP-1 class. Nausea occurred in 16% to 45% of participants across dose groups, and most gastrointestinal symptoms were mild to moderate and diminished with dose titration over 12 to 20 weeks 2.

What South Dakota Patients Should Do Now

Patients in South Dakota interested in retatrutide should begin by establishing care with a provider experienced in obesity medicine. The Obesity Medicine Association directory lists board-certified specialists across the state. A baseline evaluation including BMI, hemoglobin A1c, lipid panel, hepatic function tests, and thyroid screening will position patients for rapid initiation once the drug launches.

For patients considering compounded retatrutide now, verify that the prescribing provider has reviewed your complete medical history and that the compounding pharmacy holds a current South Dakota Board of Pharmacy license. Request batch-specific certificates of analysis showing peptide identity, purity (target: >97%), and sterility testing results. The typical starting dose in the phase 2 trial was 0.5 mg weekly, titrated over 24 weeks to the target maintenance dose of 8 mg or 12 mg 2.